Treatment and Monitoring of Gestational Trophoblastic Neoplasia Based on FIGO Risk Scoring
Use the FIGO scoring system to stratify patients into low-risk (score 0-6) versus high-risk (score ≥7) disease, then treat low-risk GTN with single-agent methotrexate with folinic acid and high-risk GTN with multi-agent EMA/CO chemotherapy, continuing treatment for 6-8 weeks after hCG normalization depending on prognostic features. 1, 2, 3
Risk Stratification Using FIGO Scoring
The FIGO 2000 scoring system remains the cornerstone for treatment decisions in GTN. Calculate the score using seven prognostic factors: age, antecedent pregnancy type, interval from index pregnancy, pretreatment hCG level, largest tumor size, metastasis sites, number of metastases, and prior failed chemotherapy 2. This scoring system specifically predicts resistance to single-agent chemotherapy and guides initial treatment selection 1.
Important caveat: The FIGO scoring system does not apply to placental site trophoblastic tumor (PSTT) or epithelioid trophoblastic tumor (ETT), which require different management approaches 1.
Low-Risk GTN (FIGO Score 0-6)
First-Line Treatment
Treat with single-agent methotrexate alternating with folinic acid (MTX/FA). This regimen is preferred in most European centers because it demonstrates less toxicity than methotrexate alone or single-agent actinomycin-D, while maintaining cure rates approaching 100% even when first-line therapy fails 1. The typical schedule involves intramuscular methotrexate alternating daily with folinic acid for 1 week, followed by 6 rest days 2.
Alternative acceptable single-agent options include actinomycin-D, though this carries higher toxicity 1.
Duration of Treatment
Continue chemotherapy for 6 weeks of maintenance treatment after hCG normalization. 1 This consolidation period is mandatory to prevent relapse, even after hCG returns to normal.
Managing Resistance
Approximately 25-30% of low-risk patients develop resistance to initial single-agent chemotherapy 4. Switch to alternative single-agent therapy or multi-agent EMA/CO if:
- hCG plateaus or rises on serial measurements
- hCG level exceeds 1,000 IU/L during treatment
- New metastases develop 3
Critical pitfall: Patients with FIGO scores of 5-6 have significantly higher resistance rates (70-80%) to first-line single-agent therapy 4. Consider more aggressive initial treatment for this subset, though current guidelines still recommend starting with single-agent therapy 1.
High-Risk GTN (FIGO Score ≥7)
First-Line Treatment
Initiate multi-agent chemotherapy with EMA/CO (etoposide, methotrexate, actinomycin-D alternating with cyclophosphamide and vincristine). 1, 2, 5 This regimen is highly effective, simple to administer, and relatively non-toxic, achieving complete response rates of 62-78% and long-term survival rates of 85-94% 5.
The more recent 2025 EOTTD-ESGO-GCIG-ISSTD guidelines confirm EMA/CO remains the standard, with survival rates exceeding 96% 3.
Induction Therapy for Ultra-High-Risk Disease
For patients with FIGO scores ≥13 or those at high risk of life-threatening bleeding (brain, liver, or extensive lung metastases), use 1-3 cycles of low-dose etoposide and cisplatin (EP) before starting EMA/CO. 1, 3 This induction approach reduces early deaths from severe bleeding and metabolic disturbances 1.
If bleeding occurs despite induction therapy, embolization of affected vessels is often helpful 3.
Duration of Treatment
Continue treatment until hCG normalization, then provide:
- 6 weeks of consolidation for standard high-risk disease 1
- 8 weeks of consolidation for poor prognostic features (liver with or without brain metastases) 1
The 2025 guidelines recommend 2-4 consolidation cycles, acknowledging some uncertainty in the exact number but emphasizing that at least 2 cycles are mandatory 3.
Brain Metastases Management
Adapted chemotherapy is required for brain metastases, and neurosurgical intervention may be necessary 3. Consider intrathecal methotrexate in selected cases 3.
Monitoring During Treatment
hCG Surveillance Schedule
Weekly hCG monitoring during active treatment, then:
- Weekly for 6 weeks post-chemotherapy
- Two-weekly until 6 months
- Monthly assessments, eventually decreasing to six-monthly 1
The more recent RCOG 2020 guideline simplifies follow-up for complete molar pregnancy: if hCG normalizes within 56 days, follow for 6 months from uterine removal; if not, follow for 6 months from normalization 2.
Imaging Requirements
For high-risk disease, obtain contrast CT of chest/abdomen and MRI of brain/pelvis at diagnosis 3. Repeat imaging is necessary when assessing for chemoresistance or relapse.
Critical warning: Metastases are often highly vascular. Biopsies can cause life-threatening bleeding and should only be obtained when safe 3.
Management of Chemoresistant/Relapsed Disease
Low-Risk Failures
Nearly all low-risk patients who fail first-line monotherapy will be cured with either sequential single-agent chemotherapy or multi-agent chemotherapy with or without surgery 4. The overall survival approaches 100% even after treatment failure 1.
High-Risk Failures
Switch to EP/EMA (etoposide and cisplatin alternating with etoposide, methotrexate, and actinomycin-D) or TE/TP regimens. 1 These salvage regimens frequently achieve remission even in resistant cases 6.
Surgery can effectively salvage patients with isolated foci of chemoresistant disease 1. Hysterectomy significantly shortens time to hCG normalization (48 vs 74 days) in low-risk disease 7.
Special Considerations
PSTT and ETT
These variants are less sensitive to chemotherapy. For stage I disease presenting within 4 years of last pregnancy, perform hysterectomy with pelvic lymph node sampling. For metastatic disease or presentation beyond 4 years, use multi-agent chemotherapy (EP/EMA) and consider high-dose chemotherapy 1.
Residual Masses
Residual lung or uterine masses following chemotherapy are not predictive of recurrence and do not require surgical excision 1. Base decisions on hCG levels, not imaging findings.
Centralization of Care
Management of GTN is optimized by centralization of care, pathology review, and hCG monitoring. 1 Discuss any second D&C or unusual presentations with a GTD reference center before proceeding 1.
Long-Term Monitoring
Continue lifelong monitoring in some centers to collect data on late effects, including second cancers 1. The risk of second malignancy is minimal with methotrexate alone but slightly elevated with combination chemotherapy, particularly if continued beyond 6 months 1. For EMA/CO specifically, there is no overall increased risk of second cancers, with a slight excess of leukemias but reduction in other cancers including breast cancer 1.
Fertility Preservation
Fertility is not significantly affected, with 83% of women becoming pregnant after either MTX/FA or EMA/CO chemotherapy 1. EMA/CO brings forward menopause by approximately 3 years 1. When pregnancy occurs, confirm normality by ultrasound and recheck hCG at 6 and 10 weeks postpartum to ensure no recurrence 1.